AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00715741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FiO2 >0.9 with 3-5 cm water PEEP
Description: FiO2 >0.9 with 3-5 cm water PEEP
Study NCT00715741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FiO2 >0.9 without PEEP
Description: FiO2 >0.9 without PEEP
Study NCT00738452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
Study NCT00738452 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
Study NCT00738452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radionuclide imaging
Description: Approximately 1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post infusion.
Study NCT00738452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single photon emission computed tomography
Description: Approximately 2 days and 3-5 days post infusion
Study NCT00738452 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 3-6 mCi Indium-111 labeled cT84.66(5mg) and dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
Study NCT00738452 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 anti-CEA monoclonal antibody cT84.66
Description: Dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
Study NCT02120885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical activity intervention
Description: Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
Study NCT03754361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: automated peritoneal dialysis
Description: peritoneal dialysis administered by a cycler
Study NCT03754361 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IHD
Description: HD 4hour 2-3times per week
Study NCT04355429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: captopril 25mg
Description: Drug administration
Study NCT02743390 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Monoclonal antibody biologic drug that inhibits tumour necrosis factor alpha (TNF-α), 3 mg/kg for 2 hours (250mL)
Study NCT02743390 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline for 2 hours (250mL)
Study NCT04055311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Resource Information Support (CRIS)
Description: Intervention support is patient initiated and accessed as needed
Study NCT04055311 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Enhanced
Description: Usual care is enhanced with the addition of the NCI Facing Forward brochure
Study NCT01876537 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hardware wound healing
Study NCT01876537 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Surgery
Study NCT00230022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief computer-delivered intervention
Description: 20-minute interaction with voice-enabled software that could provide reflections, images, text, etc.
Study NCT04142164 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MacInfo presentation
Description: Presentation about intravitreal drug injection
Study NCT04142164 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo presentation
Description: Placebo presentation
Study NCT04250350 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Subcutaneous injection
Study NCT04476342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: minimal invasive cardiopulmonary bypass (MICPB) system
Description: The experimental group was MICPB group, with built-in micro-thrombotic oxygenator and MP formula (15mL 15%KCl+10ml compound potassium, calcium and magnesium +25ml normal saline)
Study NCT00534079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase alfa (Pulmozyme)
Description: 1 x 2,5 ml per day, inhalation use, for 28 days
Study NCT00534079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dornase alfa (Pulmozyme)
Description: 1 x 2,5 ml per day, inhalation use, for 28 days
Study NCT00534079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isotonic saline
Description: 1 x 2,5 ml per day, inhalation use, for 28 days
Study NCT04108975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus muscle non reapproximation during CS
Description: During CS rectus muscle non reapproximation will be done.
Study NCT05990283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket shield technique
Description: For the patients in the shield group, shields were prepared with the Root Membrane Kit. After the palatal part was removed, the buccal fragment was prepared at the crest level, and an internal bevel chamfer was formed on the fragment. Implants were placed 3-4 mm apical to the gingival margin of the adjacent teeth. Healing caps were placed, and the periphery of the caps was covered with an absorbable gelatin sponge.
Study NCT05990283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided bone regeneration
Description: For the patients in the regeneration group, teeth were extracted atraumatically, implants were placed 3-4 mm to the gingival margin, and the space between the implant and buccal bone was filled with anorganic bovine bone graft at the time of implant placement. The graft particles were covered by a pericardium membrane. The membrane was fixed to the bone with titanium pins.
Study NCT00534079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: 1 x 2,5 ml per day, inhalation use, for 28 days
Study NCT03487341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cord drainage
Description: Cord drainage
Study NCT03487341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cord clamping
Description: Cord clamping
Study NCT02641106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Directly Observed Therapy
Description: Video Directly Observed Therapy (VDOT) is a novel means of remotely observing patients ingesting medications using videos sent from a smartphone. VDOT was developed and found to be feasible and acceptable for monitoring daily treatment of active TB in San Diego, CA and Tijuana, B.C., Mexico (R21-AI088326; PI: R. Garfein). Patients are taught how to use the VDOT recording app, record medication ingestion, and contact their physician when side effects occur. Participants are trained at the time of their first LTBI treatment dose to ensure participants know how to record videos. All remaining 11 weekly doses are taken and recorded wherever the participant chooses. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken.
Study NCT02641106 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person DOT
Description: Clinic-based, in-person DOT is the standard of care for monitoring adherence for patients taking the 12-dose isoniazid/rifapentine treatment for LTBI. Participants visit the clinic once weekly until all 12 doses are taken or 16 weeks pass, whichever comes first.
Study NCT00618384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: patients get transarterial chemoembolization (TACE) will get film-coated tablets of Sorafenib (2 x 400 mg/day) until progressive disease
Study NCT01275651 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02778334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey
Description: Patients who accept will be seen in maintenance during hospitalization in Neuro-Vascular Unit (UNV) (T0 = 4 to 7 days post-stroke)~At the time of the release of the UNV two groups:~1. patients who return home and~2. patients who continued hospitalization in rehabilitation. Depression, anxiety, quality of life and coping strategies will be assessed by self-administered questionnaires. A first phase of ambulatory (ESM / EMA) will also take place following the (UNV) output: 5 times a day for 7 days patients will respond to questions evaluating depression, anxiety and coping strategies. Patients will answer these questions via a smartphone app (issues ESM).~Another ambulatory phase on the same model as that performed at T1 (5 times daily for 7 days) accompanied by a self-assessment of depression, anxiety, coping strategies and quality of life will made 2 months post-stroke (T2).~The last time the study will take place 4 months after stroke onset (T3).
Study NCT01721915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)
Study NCT01721915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00327743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larotaxel
Description: IV infusion on Day 1 of a 21-day cycle
Study NCT00327743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: oral, twice daily, Day 1-Day 14 of a 21-day cycle
Study NCT02161003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cells Injection Technique
Description: Injection of MSCs for the treatment of anal sphincter insufficiency is a potential alternative therapy for imperforate anus patients who have undergone primary PSARP with post-operative FI. In this study a single dose of 1.2 ml MSC will be divided into 12 part of 0.1ml of MSC, doses will be injected into the anal sphincter all around in 12 injection sites according to the clock meridian under general anesthesia without giving muscle relaxant.
Study NCT02161003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Isolation
Description: From the upper posterior iliac crest 10 ml bone marrow sample will be extracted from patients using a heparinized syringe, under general anesthesia, in a suitable clean operation room.
Study NCT02137109 — intervention group
Intervention type: DRUG
Intervention: natalizumab
Description: Administered as specified in the treatment arm.
Study NCT03259828 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant image-guided radiotherapy
Description: Image-guided adjuvant radiotherapy to the sigmoid colon surgical tumor bed and pelvic regional lymph nodes: 45-50.4 Gy in 1.8 Gy/fraction
Study NCT02819245 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: posterior correction and fusion
Study NCT02781857 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT02433925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Study NCT02433925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01287091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral tablet dose
Study NCT01287091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral capsule dose
Study NCT01287091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral tablet dose in fed state
Study NCT01287091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral repeating dose in fasting state
Study NCT01287091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral repeating dose in fed state
Study NCT01287091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Oral tablet in a fasting state
Study NCT01287091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Oral repeating dose
Study NCT04167124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multi-sensor lifestyle intervention
Study NCT00459706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enbrel 50 mg Prefilled Syringe
Description: Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
Study NCT00459706 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enbrel 50 mg Autoinjector
Description: Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
Study NCT02128425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle~\*reduced in UGT1A1 7/7 patients
Study NCT02128425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: oxaliplatin 85 mg/m² + leucovorin 400 mg/m² +5-FU 400mg/m² bolus iv.+ 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
Study NCT02168374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indirect pulp treatment
Description: Carious dentine was sampled from the mesial portion of the cavity floor and the pulpal wall was entirely covered with one of the randomly selected materials: GIC containing 4.5% DOX; GIC containing 1.25% CHX or GIC as a control group. The antimicrobial concentrations were chosen based in the previous in vitro results obtained in this study. The cavities were then temporarily restored using a conventional GIC. Within 3 months after the initial treatment,the materials were carefully and completely removed, a new dentine sample was collected, and the teeth were then restored with a light-cured composite resin using a bonding system, after a new placement of the initial liner material.
Study NCT02168374 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Indirect pulp treatment
Description: Carious dentine was sampled from the mesial portion of the cavity floor and the pulpal wall was entirely covered with one of the randomly selected materials: GIC containing 4.5% DOX; GIC containing 1.25% CHX or GIC as a control group. The antimicrobial concentrations were chosen based in the previous in vitro results obtained in this study. The cavities were then temporarily restored using a conventional GIC. Within 3 months after the initial treatment,the materials were carefully and completely removed, a new dentine sample was collected, and the teeth were then restored with a light-cured composite resin using a bonding system, after a new placement of the initial liner material.
Study NCT04599725 — intervention group
Intervention type: DRUG
Intervention: medical abortion
Description: medical abortion
Study NCT00090987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: 400 mg orally once a day for up to 6 months.
Study NCT00492596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AttenueX IntraVesical System
Description: Insertion of the Solace AttenueX Intravesical System on Day 0
Study NCT00492596 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AttenueX IntraVesical System
Description: Insertion of the Solace AttenueX Intravesical System on Day 0
Study NCT00492596 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Cystoscopy with Simulated Insertion of AttenuEX Intravescial System
Study NCT02564640 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: videolaryngoscope
Description: patients intubated by using the videolaryngoscope
Study NCT02564640 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: patients intubated by using the Macintosh laryngoscope
Study NCT04154462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scribes
Description: Section 507 of the MISSION Act of 2018 mandates a two-year pilot of medical scribes in VA specialty clinics and emergency departments. Medical scribes assist health care providers by helping to administratively expedite an episode of care through the recording of patient information and updating patient records. Scribes are trained but non-licensed professionals, often deployed in emergency departments and outpatient clinic settings, that observe and document patient encounters but do not participate in clinical care.
Study NCT02140528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell injection
Description: Injection of adipose derived mesenchymal stem cell in the site of tibia fracture .
Study NCT02140528 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04642677 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: healthcare provider's recommended communication with sympathy and printed paper
Description: Patients and caregivers were received healthcare provider's recommended communication with sympathy and printed paper, Regardless of the patient's outward consciousness, talk with the patient and express empathy. Hearing will be maintained until the end. three times a day (8, 14 and 20 o'clock) during palliative sedation.
Study NCT02895308 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online psychoeducation
Description: The online intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
Study NCT02895308 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face psychoeducation
Description: The intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
Study NCT02122770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN4924
Description: MLN4924 intravenous solution.
Study NCT02122770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole tablets.
Study NCT02122770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole oral solution.
Study NCT02122770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous solution.
Study NCT02122770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous solution.
Study NCT02122770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous solution.
Study NCT02685501 — intervention group
Intervention type: OTHER
Intervention: no intervention
Study NCT02396017 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capsule endoscopy
Description: Endoscopic device
Study NCT02396017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy
Description: Endoscopic device
Study NCT02396017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol
Description: Bowel purgative
Study NCT02396017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol
Description: Bowel purgative
Study NCT01325116 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Reminder
Description: Personalized letters sent via post to the patient and their family physician at one, five, eight, and eleven months after their angiogram, sent on behalf of the interventional cardiologist. The patient letter provides a review of the role of each of the cardiac medications and urges long-term adherence. The language in the patient letter is simplified to a grade 6 level; this letter was tested for understanding and acceptability amongst a series of Cardiology patients.At the same time, close examination of data from Ontario indicated large stepwise declines in adherence at 30 and 60 days post-STEMI. To address this, patients will be provided an additional postcard type reminder two months post-STEMI.